Display options
Cite
Zhu S, Wang Q, Jiang J, et al. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer. Sci Rep. 2016;6:33894doi: 10.1038/srep33894.
Zhu, S., Wang, Q., Jiang, J., Luo, Y., & Sun, Z. (2016). A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer. Scientific reports, 633894. https://doi.org/10.1038/srep33894
Zhu, Shengsheng, et al. "A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer." Scientific reports vol. 6 (2016): 33894. doi: https://doi.org/10.1038/srep33894
Zhu S, Wang Q, Jiang J, Luo Y, Sun Z. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer. Sci Rep. 2016 Sep 22;6:33894. doi: 10.1038/srep33894. PMID: 27654169; PMCID: PMC5032167.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2016 Sep 22;6:33894. doi: 10.1038/srep33894.

A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.

Scientific reports

Shengsheng Zhu, Qinxia Wang, Juan Jiang, Yongwei Luo, Zuyue Sun

Affiliations

  1. Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai, 200032, PR China.

PMID: 27654169 PMCID: PMC5032167 DOI: 10.1038/srep33894

Abstract

LHRH receptor, is over-expressed in a variety of human tumors and, is a potential binding site for targeted metastatic prostate cancer therapy. The objectives of our study were to synthesize a bioconjugate of the LHRH analog [DLys

References

  1. J Control Release. 2003 Aug 28;91(1-2):61-73 - PubMed
  2. Pharm Res. 2003 Jun;20(6):889-96 - PubMed
  3. Biol Reprod. 2005 Nov;73(5):851-9 - PubMed
  4. J Control Release. 2012 Dec 10;164(2):108-14 - PubMed
  5. Urol Oncol. 2011 Nov-Dec;29(6):833-6 - PubMed
  6. Curr Cancer Drug Targets. 2015;15(4):314-26 - PubMed
  7. Tumori. 2013 May-Jun;99(3):439-43 - PubMed
  8. Pharm Res. 2014 Oct;31(10):2784-95 - PubMed
  9. Metallomics. 2014 Aug;6(8):1469-79 - PubMed
  10. Pharm Stat. 2011 Mar-Apr;10(2):128-34 - PubMed
  11. J Pept Sci. 2015 Mar;21(3):186-200 - PubMed
  12. Expert Opin Drug Deliv. 2012 Feb;9(2):151-69 - PubMed
  13. Australas J Dermatol. 2012 Feb;53(1):1-18 - PubMed
  14. Cancer Lett. 2006 Mar 28;234(2):109-23 - PubMed
  15. Eur J Endocrinol. 1999 Jul;141(1):1-14 - PubMed
  16. CA Cancer J Clin. 2005 Sep-Oct;55(5):300-18; quiz 323-5 - PubMed
  17. Methods. 2013 Jun 1;61(2):90-7 - PubMed
  18. Curr Opin Oncol. 2015 May;27(3):201-8 - PubMed
  19. Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):228-34 - PubMed
  20. J Biomed Nanotechnol. 2014 Dec;10(12):3462-82 - PubMed
  21. Mol Cancer Ther. 2009 Jun;8(6):1655-65 - PubMed
  22. Clin Transl Oncol. 2015 May;17(5):339-57 - PubMed
  23. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  24. Endocrine. 2009 Aug;36(1):87-97 - PubMed
  25. Int J Cancer. 2011 Oct 1;129(7):1611-23 - PubMed
  26. Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7 - PubMed
  27. Bull Cancer. 2015 Jan;102(1):57-64 - PubMed
  28. Rheum Dis Clin North Am. 1994 May;20(2):513-28 - PubMed
  29. Endocrinology. 2003 Apr;144(4):1456-63 - PubMed
  30. Int J Pharm. 2012 Jul 15;431(1-2):183-9 - PubMed
  31. Biochem Pharmacol. 2011 Jan 1;81(1):104-10 - PubMed
  32. Toxicol In Vitro. 2013 Mar;27(2):939-44 - PubMed

Publication Types